Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

The FDA approved insulin icodec (Awiqli) as the first once-weekly, long-acting basal insulin for glycemic control in adults ...

Kresladi becomes the first FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2, and ...

Some patients with type 2 diabetes will be able to switch from daily insulin injections to this first-of-its-kind once-weekly ...

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification ...

Medications for type 2 diabetes address different aspects of blood sugar management and are tailored to individual health needs. Navigating type 2 diabetes treatment options can be complex, but ...

Endogenex plans to use the funds to complete a pivotal trial of its endoscopic type 2 diabetes treatment and support a ...

Adults with insulin-deficient type 2 diabetes had a decrease in HbA1c that was maintained for 1 year after receiving a ...

The approval offers the only once‑weekly basal insulin option, providing a new treatment solution that fits different patient ...

A one-size-fits-all approach to prediabetes treatment may miss the opportunity to implement an early, more intensive, ...

Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are ...

Type 2 diabetes occurs when the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood sugar levels. Medications aim to lower blood glucose, reduce A1C, and ...